Natixis Biomarin Pharmaceutical Inc Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Natixis holds 79 shares of BMRN stock, worth $5,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$5,182

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $5,452 - $7,413	79 New	79 $5,000
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $20.7 Million - $24.5 Million	-247,093 Reduced 85.97%	40,315 $3.52 Million
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $16.1 Million - $20.8 Million	-211,293 Reduced 42.37%	287,408 $27.7 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $37.2 Million - $41.3 Million	436,729 Added 704.72%	498,701 $44.1 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $797,716 - $923,060	-9,203 Reduced 12.93%	61,972 $5.37 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $10,265 - $13,720	-117 Reduced 0.16%	71,175 $6.92 Million
Q4 2022 Feb 24, 2023	SELL	$80.93 - $108.63 $5.49 Million - $7.38 Million	-67,898 Reduced 48.78%	71,292 $7.38 Million
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $6.43 Million - $8.63 Million	-79,438 Reduced 36.33%	139,190 $14.4 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $410,800 - $484,700	-5,000 Reduced 2.24%	218,628 $18.5 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $44.3 Million - $53.8 Million	-619,214 Reduced 73.47%	223,628 $18.5 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $3.13 Million - $3.9 Million	-42,084 Reduced 4.76%	842,842 $65 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $29.2 Million - $37.2 Million	-407,019 Reduced 31.5%	884,926 $78.2 Million
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $5.93 Million - $6.78 Million	79,355 Added 6.54%	1,291,945 $99.9 Million
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $4.38 Million - $4.92 Million	57,971 Added 5.02%	1,212,590 $101 Million
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $20 Million - $24.2 Million	-267,391 Reduced 18.8%	1,154,619 $87.2 Million
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $58 Million - $72.1 Million	799,207 Added 128.32%	1,422,010 $125 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $28.3 Million - $51.5 Million	393,237 Added 171.3%	622,803 $47.4 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $10.1 Million - $15.7 Million	-126,545 Reduced 35.54%	229,566 $28.3 Million
Q1 2020 May 14, 2020	SELL	$71.37 - $96.85 $2.24 Million - $3.03 Million	-31,316 Reduced 8.08%	356,111 $30.1 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $11.6 Million - $15.6 Million	-180,783 Reduced 31.82%	387,427 $32.8 Million
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $12,603 - $15,915	187 Added 0.03%	568,210 $38.3 Million
Q2 2019 Aug 13, 2019	SELL	$80.35 - $93.9 $8.38 Million - $9.79 Million	-104,288 Reduced 15.51%	568,023 $48.7 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $11.3 Million - $13.2 Million	133,829 Added 24.85%	672,311 $59 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $1.69 Million - $2.23 Million	21,053 Added 4.07%	538,482 $45.9 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $48.6 Million - $54.7 Million	517,429 New	517,429 $50.2 Million
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $987,914 - $1.16 Million	-12,257 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	12,257	12,257 $1.11 Million

Others Institutions Holding BMRN

# of Institutions

629

Shares Held

178M

Call Options Held

1.98M

Put Options Held

1.17M

Black Rock Inc. New York, NY

22.7M
Shares

$1.49 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.26 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.24 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$912 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$688 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account